cyrilzakka/clinical-trials huggingface dataset:
Effect of Acheta Domesticus Supplementation on Post-Exercise Muscle Recovery in Recreationally Active Male

The goal of this clinical trial is to test the effect of house cricket (Acheta domesticus) supplementation for strength recovery in recreationally active males. The main question\[s\] it aims to answer are: whether house cricket powder could improve strength recovery and whether house cricket powder could be an alternative to commonly used protein supplement. Participants will do exercise (100 drop jumps) to induce fatigue and then they will consume either isocaloric carbohydrate, whey protein isolate or defatted house cricket powder for 4 days. Their strength will be measured every 24 hours for 4 days in order to observe the recovery.

Researcher will compare house cricket powder with isocaloric carbohydrate to see if the strength recovery is faster in house cricket powder group

Researcher will compare house cricket powder with whey protein isolate to see if the strength recovery is comparable.

Participants: recreationally active males Study type: double-blind randomized controlled trial

Supplement dose is tailored to each participant daily protein consumption. It aims to reach 1.4 g/kg body weight protein, hence participant is required to provide dietary record 3 days before the experiment and during the experiment. Subject will attend one familiarization 1 week before the experiment. During day one of the experiment, subject warmed up before the session. Then their baseline strength and jumping measurement will be taken. Afterwards, they will do 20 reps of drop jumps for 5 sets (each set separated by 2 minutes rest). Immediately after the exercise, they will consume either whey, house cricket or maltodextrin. 10 minutes afterwards, they will undergo another strength and jumping measurement. 24, 48 and 72 hours after the exercise, subject will come for strength and jumping post-test after consuming the supplement. They are also required to fill in a visual analogue scale and 7-points Likert scale form regarding their pain and soreness perception.

Eligibility Criteria:
Inclusion Criteria:

* 5-10 hours of exercise per week

Exclusion Criteria:

* smoking
* drinking alcohol
* history of surgical/medical procedure that could affect the study
* food allergy
* in medication
* have participated in similar studies before
An Imaging-based Quantitative Biomarker Assay for NAFLD in Children

This study will validate recently developed Magnetic Resonance Imaging (MRI) and Ultrasound (US) based methods for liver fat quantification in children with obesity and healthy range of body mass index (BMI).

The severity of the obesity epidemic in the U.S., particularly in Wisconsin, is alarming, with overall overweight or obesity rates of 35% in children. \[Fryar 2020,\] Obesity is a major risk factor for several comorbidities, one of the most common being non-alcoholic fatty liver disease (NAFLD, also denoted steatotic liver disease). The inflammatory state known as non-alcoholic steatohepatitis (NASH) may lead to fibrosis and, if left untreated, can lead to cirrhosis, liver failure, and cancer. For these reasons, there is enormous interest in effective interventions for weight loss and reversing NAFLD. A central challenge in the development of new interventions is the need for accurate and precise biomarkers to evaluate hepatic steatosis in children.

This pilot study focuses on demonstrating the feasibility of MRI and US based liver fat quantification in children and addresses technical challenges that may limit the performance of the proposed techniques in the population of interest through the following aims:

* Aim 1: Determine the bias and precision (repeatability) of emerging free-breathing MRI-based liver fat quantification in children with obesity and controls using current breath-held methods as a reference.
* Aim 2: Determine the precision (repeatability and reproducibility) of US-based biomarkers of liver steatosis with a focus on the impact of body wall thickness on the precision of the biomarkers.

Eligibility Criteria:
Inclusion Criteria:

1. Age: 10 - 14years old
2. BMI: Case subjects: BMI\>95th percentile for age and sex Healthy BMI volunteers: 5th ≤ BMI \< 85th percentile for age and sex

Exclusion Criteria:

1. Children with contraindications to MRI.
2. Children who did not fast (verbally confirmed by children or guardian)
3. Pregnant
Performance of Curing Times and Intensitis

The aim of the study is to compare the effect of high intensity light cure (2200 mw/cm2) for 1 second with low intensity light cure (1200 mw/cm2) for 20 seconds on the clinical performance of bulk fill resin composite restorations in compound Class II cavities of posterior teeth

The prepared cavities will be conditioned with 35% phosphoric acid gel for15 seconds, then will be rinsed and dried with compressed air. Then application of universal adhesive system to all cavity with bond brush then light cured for 10 seconds using LED light curing unit (1200 mw/cm2). Extra-Fill bulk fill resin composite will be applied in onebulk increment and will be light polymerized for 1 second using (LED) light curing unit (2200 mw/cm2).for intervention group Extra-Fill bulk fill resin composite will be applied in one bulk increment and will be light polymerized for 20 seconds using (LED) light curing unit (1200 mw/cm2) fot control group

Eligibility Criteria:
Inclusion Criteria:

* Permanent premolars or molars.
* Moderate to deep compound class II cavities.
* Vital with the positive reaction to a cold thermal stimulus.
* Absence of parafunctional habits

Exclusion Criteria:

* Teeth with clinical symptoms of pulpitis such as spontaneous pain or sensitivity to pressure.
* Non-vital teeth.
* Secondary carious lesions.
* Advanced periodontal disease
Treatment Patterns, Outcomes and Resource Use Study for Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-squamous) in the Kingdom of Saudi Arabia and United Arab Emirates

A retrospective observational longitudinal medical chart review study of randomly sampled patients diagnosed with advanced/metastatic NSCLC. The minimum observational period for each patient will be 12 months.


Eligibility Criteria:
Inclusion Criteria:

* Adults 18 years and older at the time of advanced/metastatic NSCLC diagnosis, and currently alive or deceased
* Histologically confirmed diagnosis of advanced/metastatic NSCLC (squamous, non-squamous or NOS) stages IIIB/IV. First diagnosis of advanced/metastatic NSCLC between 01-Jan-2010 and 31-Mar-2014 (currently alive or deceased) with a minimum 12 months of potential observation period available in medical records
* Medical history and treatment data must be available (or obtainable by SI) for chart abstraction from the date of advanced/metastatic diagnosis through most recent patient follow-up/contact. This also includes documentation of treatment by other physicians and inpatient hospital treatments within KSA or the Health Authority of Abu Dhabi (HAAD) system
* Patients must have at least all data on age, gender, date of advanced NSCLC diagnosis, Line of Treatment (LOT) information (agent types and dosage), and date of last follow-up

Exclusion Criteria:

* Patient had enrolled in a cancer treatment-related clinical study at any time after the diagnosis of advanced/metastatic NSCLC
Anxiety Level of Child and Parents During Preoperative Anesthesia Evaluation

1. Appreciation of preoperative anxiety in children is important for the anesthesiologist.
2. Several factors defined to effect the anxiety levels preoperatively in children such as , age, previous medical encounters , education level and parental anxiety. 3. This information was tested for Turkish children during the preoperative anesthetic evaluation.

1. Before the planned surgery all children accompanying parents filled a questionnaire about the demographics, marital status, economical conditions, education level and other diseases and operations in the family.
2. Both the parent and child filled State and Trait Anxiety tests specially prepared for adults Spielberger Anxiety tests and children defined and validation tests had already been proven.

Statistical analysis performed for evaluation.

Eligibility Criteria:
Inclusion Criteria:

* Legible

Exclusion Criteria:

* Illegible due to lack of education or eye diseases
Hospital Management and 1-year Outcome of Patients Aged 70 Years and Older With Severe COVID-19

SARS-COV-2 infection can progress to acute respiratory distress syndrome and require hospitalization in the ICU in 5-20% of affected patients. Age is a major risk factor for developing a severe form and for death. ARDS related to SARS-COV-2 has specific features, including the need for long mechanical ventilation and length of stay and the use of corticosteroid therapy. These specificities are responsible for significant morbidity (neuromyopathy, delirium, post-resuscitation syndrome) and mortality during the first wave (46% at 3 months for the population of patients aged 70 years and over). To investigator's knowledge, no study has evaluated the prognosis in the ICU and the long-term functional outcome of elderly people admitted for a severe or critical form of COVID-19 since the major changes in management (dexamethasone, screening for thrombo-embolic complications, use of high-flow oxygen therapy as first-line treatment...).

Investigator therefore propose a 1-year follow-up of a cohort of patients aged 70 and over hospitalised in a conventional service or in intensive care for a severe or critical form of COVID-19. The objectives are to describe the prognosis and functional outcome of hospitalized elderly patients with severe COVID-19.


Eligibility Criteria:
Inclusion Criteria:

* age ≥ 70 years on admission to hospital
* diagnosis of SARS-CoV-2 infection defined by a positive RT-PCR test
* medical or critical care hospitalisation between 1 July 2020 and 31 August 2021
* who experienced severe hypoxaemic acute respiratory failure defined as at least 4L/min of oxygen during hospitalisation

Exclusion Criteria:

* Oxygen therapy \< 4L/min during hospitalisation
* Mc Cabe score 3 (chronic disease fatal at 1 year such as stage IV heart failure, ventilated respiratory failure, metastatic cancer, Child C cirrhosis)
* dementia or cognitive disorders before hospitalisation reported in the medical record
* patient GIR 1 to 4 before hospitalisation reported in the medical file or deduced from the description of the lifestyle
* patient with an ADL score \< 4 before hospitalisation reported in the medical record or deduced from the description of lifestyle
* patient living in EHPAD before hospitalisation
* non-French speaking patient
* patient under guardianship or curatorship
* refusal to participate in the study for patients surviving 1 year or refusal by a family member or trusted person
Antibiotic Prophylaxis in Ragged Placental Membranes

In some centres, women are routinely given a course of antibiotics postnatally if ragged placental membranes were present at delivery. The investigators examined the necessity such an intervention.

Postpartum endometritis resulting in sepsis remain one of the leading cause of maternal mortality in developing countries. Ragged placental membrane is a risk factor for endometritis and is not infrequently encountered. Several hospitals in Malaysia, largely those geographically-removed currently practice administering prophylactic antibiotics for women with ragged placental membranes. The aim is to reduce the risk of postpartum endometritis in a subgroup of women who may present in dire straits. The investigators sought to examine the necessity of such protocols.

Eligibility Criteria:
Inclusion Criteria:

All women who delivered vaginally beyond 24+0 weeks of gestation and were found to have ragged or retained placental membranes immediately after the third stage of labour were invited to participate in the study.

Exclusion Criteria:

1. Fever, within 5 days preceding delivery (Axillary temperature \> 37.5oC on 2 or more occasions at least 1 hour apart or temperature \> 38oC on one occasion). This also includes intrapartum fever.
2. Required oral or intravenous antibiotics for any other obstetric-related (ex. third or fourth degree tears, preterm prelabour rupture of membranes) or non- obstetric related (ex. pneumonia, acute pyelonephritis) reasons
3. Prolonged rupture of membrane (\>18 hours)
4. Retroviral disease, on long term oral or parenteral steroid or receiving other forms of immunosuppressants, including chemotherapy within the last one year.
5. Vaginal delivery for an intrauterine death
6. Penicillin allergy
The HELlenic Thoracic Society Initiative for CΟPD and CVD

COPD is one of the most common respiratory diseases in Greece, and maybe more than half a million Greek citizens suffer both from COPD and CVD, however their characteristics and management remain unknown. HELICOPD is a national, multicenter, prospective, non-interventional study designed to contribute to better understanding and depicting the demographic and clinical characteristics of this population, the COPD- and CVD-related adverse events in a two-years period, their quality of life and the healthcare resources use. The study is initiated and coordinated by the Hellenic Thoracic Society.


Eligibility Criteria:
Inclusion criteria

Patients should cumulatively meet the following three (3) criteria to be enrolled in the study:

1. To have been diagnosed with chronic obstructive pulmonary disease and at least one cardiovascular comorbidity (heart failure, atherosclerotic cardiovascular disease, atrial Fibrillation, severe valvular disease)
2. Adults aged \&gt;35 years at the time of inclusion in the study,
3. With signed informed consent for their participation in the study. Exclusion criteria Patients with the below limitations are not eligible to participate in the study

Patients:

1. Without at least one cardiovascular comorbidity,
2. With history of lung cancer
3. With any other active malignancy and undergoing treatment (chemotherapy/radiotherapy/immunotherapy)
4. With any thoracic or abdominal surgery planned during study follow-up period
5. With participation in any COPD-related interventional study at study entry or during study duration.
6. Without signed informed consent for their participation in the study.
3D Single Cell Analysis Using Cell Morphology and Organelle Scattering Texture

The investigators will use an advanced high resolution 3D optical coherence tomography (OCT) technology to observe colon and skin images in ex vivo.

Achieved formalin-fixed paraffin embedded tissue specimens from colon cancers and/or other benign and pre-cancer colon lesions as well as melanoma and/or other benign pigmented skin lesions will be used. The achieved specimens were kept in Department of Pathology, National Taiwan University Hospital. Sections of achieved pathological specimens were put on glass slides and tissue image will be observed by 3D optical coherence tomography (OCT). The 3D optic tomography system utilize a Ce:YAG optical fiber as light source and also combined with confocal microscopy. Taken together, these features made the 3D optic tomography system have very high resolution and suitable for single cell imaging. This study will not interfere with the normal medical practice and had no impact on patient's safety and health. All of the materials will be destroyed once the experiments are done. The enrollment criteria will be patients who underwent colon/skin surgery or examinations in NTUH with pathological specimens taken and stored at NTUH.

Eligibility Criteria:
Inclusion Criteria:

• Participants are those who who received skin or colon surgery, with their surgical specimens preserved and stored at Department of Pathology, National Taiwan University Hospital.

Exclusion Criteria:

• Age younger than 20 years old.
Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy

The purpose of this study is to determine whether Renexin is effective in the treatment of vestibular symptoms in patients with recurrent vestibulopathy.

1. Study design

   * Among patients who visitied for recurrent vertigo more than 3 months, patients will be included after ruling out other peripheral vertigo through history taking, physical examination, Dix-Hallpike test, head-thrust test.
   * Included patients will go through permission, laboratory tests (CBC, chemical battery, coagulation battery, urine HCG (only women of childbearing age), posturography. During patients selection period for inclusion(2 weeks), taking medication for vertigo is prohibited.
   * Included patients will be randomized to Treatment group (Renexin) and Placebo group.
   * All patients before treatment will do dizziness handicap inventory(DHI), visual analogue scale (VAS) for vertigo, questionnaire for quality of life (SF36).
   * After 4 weeks(+-\~ 3 days) of drug administration, DHI, VAS for vertigo, SF36 will be done for drug compliance and side effects.
   * After 8 weeks(+-\~ 3 days) of drug administration, posturography, DHI, VAS for vertigo, SF36 will be done for drug compliance and side effects.
   * For control of severe vertigo during drug administration, Valium 2mg can be used as a salvage treatment, and number of valium administration will be checked at every visit.
2. Statistical analysis

   * As a statistical analysis, paired T-test will be used to compare equilibrium score, DHI, VAS, SF-36. When p-value is \<0.05, it will be considered as significant difference.

Eligibility Criteria:
Inclusion Criteria:

* Recurrent vestibulopathy patient with symptoms more than 3 months of recurrent vertigo
* Visual analogue scale (VAS) score between 4 to 8

Exclusion Criteria:

* Showing signs of central lesion in MRI or neurologic exams
* central nystagmus or loss of consciousness with vertigo
* cerebellar symptoms such as ataxia, dysarthria, gait disturbance
* Diagnosed as peripheral vertigo such as benign paroxysmal positional vertigo, Meniere's disease, migrainous vertigo in recent 3 months
* Bilateral vestibular dysfunction
* Vestibular neuronitis symptom appeared in recent 6 months
* Chronic liver disease (ALT\>100 or AST\>100) or chronic kidney disease (Creatinine \> 3.0 mg)
* Blood Hemoglobin \< 10mg/dl (in male) or \< 8 mg/dl (in female)
* Contraindication for testing drug (ex. Pregnancy or breast feeding etc.)
* Taking antiepileptics such as phenobarbital, phenytoin, carbamazepine or rifampin in recent 2 weeks
* Taking cilostazol, gingko biloba for other disease
* Allergy/hypersensitivity to Renexin
* Severe drug toxicity when taking Renexin previously
320 Multidetector Computed Tomography Prior to Coronary Artery Bypass Surgery

Recent advances in technology have resulted in the development of scanners that can n image the heart arteries within 10 to 20 minutes but without the need for admission to hospital or insertion of catheters. This means that coronary heart disease may be more readily identified (or ruled out) and allow better diagnosis and treatment of patients with symptoms suggesting coronary heart disease. Here, we propose to assess the latest and most powerful scanners to see if it can accurately diagnose the extent of coronary artery disease and facilitate the planning of heart surgery.


Eligibility Criteria:
Inclusion Criteria:

* patients who have undergone conventional coronary angiography and have been referred for coronary artery bypass surgery or valve replacement

Exclusion Criteria:

* age less than 18
* pregnancy or breast feeding
* inability to undergo computed tomography scanning
* inability to give informed consent
* severe renal failure (serum creatinine \>250umol/l or estimated glomerular filtration rate \<15ml/min)
* known allergy to iodinated contrast
Vitamin D Oral Replacement in Asthma

The overall objective of the study is to determine the pharmacokinetics of Vitamin D supplementation in children who have asthma and are overweight or obese.

This study has two parts. In part 1, study participants will be randomized to receive one of four doses of vitamin D supplementation in international units (IU) over at 16-week period: 1) Single 50,000 IU loading dose + 6000 IU daily dose; 2) Single 50,000 IU loading dose + 10,000 IU daily dose: 3) 6000 IU daily dose; or 4) 600 IU daily dose. Based on pharmacokinetic analysis, one of the doses (1-3) will be selected to use in part 2.

In part 2, study participants will be randomized to the dose selected in part 1 or the 600 IU daily dose of vitamin D supplementation to be administered over a 16-week dosing period.

Across both parts, safety of each dose regimen of vitamin D supplementation will be evaluated, and the effectiveness of each dose to achieve a serum level of 25(OH)D greater than or equal to 40 ng/ml will be assessed.

Eligibility Criteria:
Inclusion Criteria:

* Body mass index greater than or equal to 85% for age and sex
* Physician-diagnosed asthma
* Ongoing relationship with asthma provider responsible for asthma care
* Serum 25(OH) D level 10 ng/ml to less than 30 ng/ml at screening visit based on local laboratory test
* Ability to swallow pills similar in size to the vitamin D preparation to be used
* Signed consent form from parent, legal guardian or caregiver and signed assent from participant (as appropriate)
* Females of childbearing years must not be pregnant, must not be lactating and must agree to practice adequate birth control method
* Child and parent, legal guardian, or caregiver must speak English or Spanish

Exclusion Criteria:

* Known diseases of calcium metabolism or the parathyroid
* History of renal insufficiency or kidney stones
* Known liver failure or history of abnormal liver function tests
* History of Williams syndrome, sarcoidosis, or granulomatous disease
* Active tuberculosis
* Spot urine calcium/creatinine ration greater than 0.37 (calcium and creatinine measured in mg/ml). This can be repeated following adequate hydration
* Clinical evidence of rickets
* Taking supplemental vitamin D greater than equal to 1000 IU per day
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers

This is a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study conducted in three parts.


Eligibility Criteria:
Key Inclusion Criteria:

* Body mass index 18.5 to 35.0 kg/m², inclusive, and body weight of at least 50.0 kg at screening
* In good health, determined by no clinically significant findings from medical history, physical examination, and vital sign measurements
* Women of non-childbearing potential and men using contraceptive measures

Key Exclusion Criteria:

* History of clinically significant hematological, renal, pancreatic, gastrointestinal, hepatic, cardiovascular, metabolic, endocrine, immunological, allergic disease, or other major disorders
* History of asthma, chronic obstructive pulmonary disease, or emphysema
* Clinically significant neurologic disorder
* History of stomach or intestinal surgery or resection
* History of malignancy